174 related articles for article (PubMed ID: 38645565)
1. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
[No Abstract] [Full Text] [Related]
2. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
4. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
[TBL] [Abstract][Full Text] [Related]
7. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
[TBL] [Abstract][Full Text] [Related]
8. An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.
Pei J; Gao Y; Wu A
Front Immunol; 2024; 15():1369726. PubMed ID: 38742117
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
Park JH; McMillan DC; Powell AG; Richards CH; Horgan PG; Edwards J; Roxburgh CS
Clin Cancer Res; 2015 Feb; 21(4):882-8. PubMed ID: 25473000
[TBL] [Abstract][Full Text] [Related]
10. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
11. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
12. Host-microbiota interactions contributing to the heterogeneous tumor microenvironment in colorectal cancer.
Li X; Wu D; Li Q; Gu J; Gao W; Zhu X; Yin W; Zhu R; Zhu L; Jiao N
Physiol Genomics; 2024 Feb; 56(2):221-234. PubMed ID: 38073489
[TBL] [Abstract][Full Text] [Related]
13. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
14. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Budding in Pretreatment Biopsies, among Tumor Microenvironmental Components, Can Predict Prognosis and Neoadjuvant Therapy Response in Colorectal Adenocarcinoma.
Yim K; Jang WM; Cho U; Sun S; Chong Y; Seo KJ
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888645
[No Abstract] [Full Text] [Related]
16. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
18. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
19. Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases.
Shimura T; Toiyama Y; Saigusa S; Imaoka H; Okigami M; Fujikawa H; Hiro J; Kobayashi M; Ohi M; Araki T; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Int J Clin Oncol; 2017 Aug; 22(4):758-766. PubMed ID: 28299463
[TBL] [Abstract][Full Text] [Related]
20. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]